Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with a Diameter >8 Cm: A Retrospective Study
Hongjie Cai,1 Song Chen,2 Zhiqiang Wu,1 Fan Wang,1 Shuangyan Tang,1 Ludan Chen,1 Wenbo Guo1 1Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510062, People’s Republic of China; 2Department of Minimally Invasive Interventional Therapy, Sun Y...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-02-01
|
| Series: | Journal of Hepatocellular Carcinoma |
| Subjects: | |
| Online Access: | https://www.dovepress.com/atezolizumab-plus-bevacizumab-combined-with-transarterial-embolization-peer-reviewed-fulltext-article-JHC |
| _version_ | 1797279374153613312 |
|---|---|
| author | Cai H Chen S Wu Z Wang F Tang S Chen L Guo W |
| author_facet | Cai H Chen S Wu Z Wang F Tang S Chen L Guo W |
| author_sort | Cai H |
| collection | DOAJ |
| description | Hongjie Cai,1 Song Chen,2 Zhiqiang Wu,1 Fan Wang,1 Shuangyan Tang,1 Ludan Chen,1 Wenbo Guo1 1Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510062, People’s Republic of China; 2Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center and Sun Yat-Sen University State Key Laboratory of Oncology in South China, and Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People’s Republic of ChinaCorrespondence: Wenbo Guo, Email guowenbo@mail.sysu.edu.cnPurpose: Local in combination with systemic therapy might be an option for patients with advanced unresectable hepatocellular carcinoma (uHCC). This study examined the clinical benefits and adverse events (AEs) of first-line transarterial embolization (TAE) and hepatic arterial infusion chemotherapy (HAIC) combined with atezolizumab (Atezo) and bevacizumab (Bev) in patients with uHCC of a diameter larger than 8 cm.Patients and methods: This retrospective study included patients with uHCC of a diameter larger than 8 cm who were treated with first-line Atezo-Bev and TAE+HAIC at the First Affiliated Hospital of Sun Yat-Sen University between September 30, 2019, and September 30, 2022. Progression-free survival (PFS), overall survival (OS), tumor response according to mRECIST, and AEs were analyzed. Multivariable Cox analyses were performed to examine the factors associated with PFS.Results: Thirty patients were included. The objective response rate (ORR) was 74.4% (95% confidence interval [CI], 59.3%-89.5%), and the disease control rate (DCR) was 93.3% (95% CI, 85.4%-98.6%). The median follow-up was 11.4 (inter-quartile range [IQR], 5.5– 17.9) months. The median PFS was 6.8 (95% CI, 2.6– 11.1) months. The 3-, 6-, 9-, and 12-month survival rates were 86.2%, 82.5%, 68.6%, and 60%, respectively. The median OS was not estimated. Extrahepatic metastasis was independently associated with PFS (hazard ratio [HR]=3.468, 95% CI, 1.001– 12.023). The most common AEs were fever (46.7%). Grade 4 AEs occurred one time as hematemesis but no 5 AEs were observed.Conclusion: Atezo-Bev combined with TAE and HAIC might benefit patients with uHCC of a diameter larger than 8 cm, with manageable AEs.Keywords: immune checkpoint inhibitors, tyrosine kine inhibitors, local therapy, systemic therapy, large unresectable hepatocellular carcinoma |
| first_indexed | 2024-03-07T16:24:20Z |
| format | Article |
| id | doaj.art-28abb76f13f544d2a43f0d7143bdfc44 |
| institution | Directory Open Access Journal |
| issn | 2253-5969 |
| language | English |
| last_indexed | 2024-03-07T16:24:20Z |
| publishDate | 2024-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Hepatocellular Carcinoma |
| spelling | doaj.art-28abb76f13f544d2a43f0d7143bdfc442024-03-03T18:36:48ZengDove Medical PressJournal of Hepatocellular Carcinoma2253-59692024-02-01Volume 1139940990746Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with a Diameter >8 Cm: A Retrospective StudyCai HChen SWu ZWang FTang SChen LGuo WHongjie Cai,1 Song Chen,2 Zhiqiang Wu,1 Fan Wang,1 Shuangyan Tang,1 Ludan Chen,1 Wenbo Guo1 1Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510062, People’s Republic of China; 2Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center and Sun Yat-Sen University State Key Laboratory of Oncology in South China, and Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People’s Republic of ChinaCorrespondence: Wenbo Guo, Email guowenbo@mail.sysu.edu.cnPurpose: Local in combination with systemic therapy might be an option for patients with advanced unresectable hepatocellular carcinoma (uHCC). This study examined the clinical benefits and adverse events (AEs) of first-line transarterial embolization (TAE) and hepatic arterial infusion chemotherapy (HAIC) combined with atezolizumab (Atezo) and bevacizumab (Bev) in patients with uHCC of a diameter larger than 8 cm.Patients and methods: This retrospective study included patients with uHCC of a diameter larger than 8 cm who were treated with first-line Atezo-Bev and TAE+HAIC at the First Affiliated Hospital of Sun Yat-Sen University between September 30, 2019, and September 30, 2022. Progression-free survival (PFS), overall survival (OS), tumor response according to mRECIST, and AEs were analyzed. Multivariable Cox analyses were performed to examine the factors associated with PFS.Results: Thirty patients were included. The objective response rate (ORR) was 74.4% (95% confidence interval [CI], 59.3%-89.5%), and the disease control rate (DCR) was 93.3% (95% CI, 85.4%-98.6%). The median follow-up was 11.4 (inter-quartile range [IQR], 5.5– 17.9) months. The median PFS was 6.8 (95% CI, 2.6– 11.1) months. The 3-, 6-, 9-, and 12-month survival rates were 86.2%, 82.5%, 68.6%, and 60%, respectively. The median OS was not estimated. Extrahepatic metastasis was independently associated with PFS (hazard ratio [HR]=3.468, 95% CI, 1.001– 12.023). The most common AEs were fever (46.7%). Grade 4 AEs occurred one time as hematemesis but no 5 AEs were observed.Conclusion: Atezo-Bev combined with TAE and HAIC might benefit patients with uHCC of a diameter larger than 8 cm, with manageable AEs.Keywords: immune checkpoint inhibitors, tyrosine kine inhibitors, local therapy, systemic therapy, large unresectable hepatocellular carcinomahttps://www.dovepress.com/atezolizumab-plus-bevacizumab-combined-with-transarterial-embolization-peer-reviewed-fulltext-article-JHCimmune checkpoint inhibitorstyrosine kine inhibitorslocal therapysystemic therapylarge unresectable hepatocellular carcinoma. |
| spellingShingle | Cai H Chen S Wu Z Wang F Tang S Chen L Guo W Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with a Diameter >8 Cm: A Retrospective Study Journal of Hepatocellular Carcinoma immune checkpoint inhibitors tyrosine kine inhibitors local therapy systemic therapy large unresectable hepatocellular carcinoma. |
| title | Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with a Diameter >8 Cm: A Retrospective Study |
| title_full | Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with a Diameter >8 Cm: A Retrospective Study |
| title_fullStr | Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with a Diameter >8 Cm: A Retrospective Study |
| title_full_unstemmed | Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with a Diameter >8 Cm: A Retrospective Study |
| title_short | Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with a Diameter >8 Cm: A Retrospective Study |
| title_sort | atezolizumab plus bevacizumab combined with transarterial embolization plus hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with a diameter gt 8 cm a retrospective study |
| topic | immune checkpoint inhibitors tyrosine kine inhibitors local therapy systemic therapy large unresectable hepatocellular carcinoma. |
| url | https://www.dovepress.com/atezolizumab-plus-bevacizumab-combined-with-transarterial-embolization-peer-reviewed-fulltext-article-JHC |
| work_keys_str_mv | AT caih atezolizumabplusbevacizumabcombinedwithtransarterialembolizationplushepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinomawithadiametergt8cmaretrospectivestudy AT chens atezolizumabplusbevacizumabcombinedwithtransarterialembolizationplushepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinomawithadiametergt8cmaretrospectivestudy AT wuz atezolizumabplusbevacizumabcombinedwithtransarterialembolizationplushepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinomawithadiametergt8cmaretrospectivestudy AT wangf atezolizumabplusbevacizumabcombinedwithtransarterialembolizationplushepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinomawithadiametergt8cmaretrospectivestudy AT tangs atezolizumabplusbevacizumabcombinedwithtransarterialembolizationplushepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinomawithadiametergt8cmaretrospectivestudy AT chenl atezolizumabplusbevacizumabcombinedwithtransarterialembolizationplushepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinomawithadiametergt8cmaretrospectivestudy AT guow atezolizumabplusbevacizumabcombinedwithtransarterialembolizationplushepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinomawithadiametergt8cmaretrospectivestudy |